2016). Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6. European Journal of Pharmaceutical Sciences, 92, 131-136. https://doi.Abstract Purpose Determining metabolic ratio from single-point plasma is potentially a good phenotyping method of CYP2D6 to reduce the required time interval and increase the reliability of data. It is difficult to conduct large sample size clinical trials to evaluate this phenotyping method for multiple plasma points. A physiologically based pharmacokinetic (PBPK) model can be developed to do simulations based on the large virtual Chinese population and evaluate single-point plasma phenotyping method of CYP2D6. Methods Pharmacokinetic data of dextromethorphan (DM) and its metabolite dextrorphan (DX) after oral administration were used for model development. The SimCYP ® model incorporating Chinese demographic, physiological, and enzyme data was used to simulate DM and DX pharmacokinetics in different phenotype groups.
Introduction
Cytochrome P450 2D6 (CYP2D6) is one of the most widely investigated polymorphic enzymes owing to its wide inter-individual and inter-ethnic variability. So far, more than 100 allelic variants have been identified (http://www.cypalleles.ki.se/).
Phenotypes are stratified and include poor (PM), intermediate (IM), extensive (EM), and ultra-rapid (UM) metabolizer phenotypes. [1] Differing enzyme activities can result in dose-dependent adverse events or therapeutic failures after administration of CYP2D6 substrates. [2] For instance, CYP2D6 polymorphism affects the clinical outcome of psychoactive drugs. The meta-analysis by Kirchheineret al [19] reveals that the dosage of about 50% of the commonly used antipsychotics is dependent on the CYP2D6 phenotype.
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It is convenient to test genotypes clinically. But given the large number of allelic variants and the presence of structural and copy number variability, it is a challenge to determine the genotype of CYP2D6. Besides, there is big uncertainty in the prediction of the large-scale enzyme activities from genotypes of CYP2D6, given the number of allelic variants and resulting complexity of allele combinations. [1, 2] Measured phenotypes should provide the most reliable data for enzyme activities.
Determining the phenotype of CYP2D6 before administration of substrates with narrow therapeutic index will be beneficial for dose adjustment while cost, time and clinical convenience are considered. Debrisoquine and dextromethorphan (DM) were suggested as the best CYP2D6 phenotyping drugs, with debrisoquine having the problem of very limited availability as a therapeutic drug. [22] So dextromethorphan was currently the most preferred probe drug for CYP2D6 metabolic activity assessment in vivo. [2, 20, 21, 22] Eight-hour urinary metabolic ratio (MR) of dextromethorphan to dextrorphan (DX) is widely used to differentiate between EM and PM. However urine collection for 8 hours could be demanding and especially inconvenient for outpatients. Therefore alternative procedures have been developed for easier and quicker phenotyping. Phenotyping method based on single-point plasma sample has been developed. [3, 4] including EMs and PMs. [4] Hu et al. [3] suggested MR DM/DX measured in single-point plasma (at any point between 1 to 5 h or at 8 h) was feasible for determining the phenotype of CYP2D6 in EMs and IMs base on data from 12 healthy Chinese subjects. [3] Determining MR DM/DX from single-point plasma is potentially a good way to reduce the required time interval and increase the reliability of data. Clinical studies are typically designed to evaluate the plasma phenotyping methods, such as Hu's study. [3] But it is difficult to conduct large sample size clinical trials to assess the phenotyping method for multiple plasma points, given that many blood samples are
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taken from each subject. Therefore the sample size is quite small when multiple plasma points are targeted. It is well known that data from small trials can't describe the inter-individual variability or the polymorphism-associated effects on pharmacokinetics well, given the wide range of CYP2D6 activities resulting from the allelic diversity. Moreover, it is hard to include subjects with all phenotypes in a small trial, in light of the low frequency of IMs in Caucasian and low frequency of PMs in Asian. The results obtained in EMs and IMs [3] 
Methods
General
Model development
The input parameters for the DM model are summarized in Table 1 . The DM model
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used the advanced dissolution, absorption and metabolism (ADAM) model for absorption. [5] A default minimal PBPK model was applied for distribution. The minimal PBPK model could be described as a "lumped" PBPK model which, in its simplest form, has only four compartments, predicting only the systemic, portal vein and liver concentrations. The default value of volume of distribution at steady state (V ss ) for DM model in SimCYP was 14.3L/kg and was reset to 16.0 L/kg. [6] CYP3A4-, 2B6-, 2C9-, 2C18-, and 2C19-mediated intrinsic clearance values (CL int,3A4 , CL int,2B6 , CL int,2C9 , CL int,2C18 , and CL int,2C19 ) were the default values in DM file in SimCYP library.
CYP2D6-mediated intrinsic clearance (CL int,2D6 ) was estimated in SimCYP by simultaneously fitting the observed mean plasma concentration-time profiles extracted from previous publications [7] for PM subjects and from unpublished data PMs were used instead. Some ethnicity dependent factors, e.g. diet, can affect the exposures of drugs. Therefore, AUC values of DM between Caucasian EMs [7, 11, 17, 18] and Chinese EMs were compared to assess the ethnicity-dependent difference. A predefined twofold deviation boundary -a measure commonly used by others [8] [9] [10] was used to evaluate the difference, which was to say a twofold deviation was allowed. PK profiles of DM in Caucasian PMs would be corrected by a correction coefficient only if the deviation between Caucasian EMs and Chinese EMs was larger (Dollery, 1992) . [23] c. Pfizer in-house data.
d. Reported (Capon et al., 1996) . [7] e. Reported (Moghadamnia et al., 2003) . [6] f. CL int,2D6 was estimated in SimCYP by simultaneously fitting observed concentration-time profiles of dextromethorphan extracted from unpublished data of EM and IM subjects, and from previously reported data of PM subjects (Capon et al., 1996) . [7] g. Scaled up from reported V max and K m (Yu and Haining, 2001) [24] using the abundance and inter system extrapolation factor (ISEF) values in SimCYP version 13.0.
A C C E P T E D M A N U S C R I P T
ACCEPTED MANUSCRIPT
h. Predicted by the prediction toolbox in SimCYP.
i. Reported median CL R of dextromethorphan: 9.0 L/h (Capon et al., 1996) . [7] Input parameters for DX were obtained from the literature ( Table 2) . For distribution, a minimal PBPK model with one compartment was applied. The V ss was the calculated mean value of reported distribution volumes of DM in literature. [12, 13] The CL int,3A4 was estimated in SimCYP by fitting observed plasma concentration-time profiles from unpublished data. All parameters of DX were identical across the three phenotype populations. [13] c. Reported (Lutz and Isoherranen, 2011). [14] d. Calculated mean value of reported V d in literature (Albers et al., 1995; Ke et al., 2013) . [12, 13] e. CL int,3A4 was estimated in SimCYP by simultaneously fitting observed concentration-time profiles of dextrorphan extracted from unpublished data of EM and IM subjects.
f. Predicted by the prediction toolbox in SimCYP.
g. Optimized (Ke et al., 2013) . [13] Simulation Simulations were based on virtual Chinese healthy populations by matching distributions of age and sex to the actual study data (age from 27 to 37 y, all male). The metric for assessing predictive performance of the PBPK model of DM and DX was the ratio of the predicted to the observed mean exposure, with the exposure defined as C max or AUC. Two thresholds of 0.8-1.25 and 0.5-2 were predefined for both C max and AUC. [15] Model application
Input parameters from
The calculated frequencies of UM, EM, IM, and PM of CYP2D6 in Chinese population were 1.84%, 47.9%, 49.3%, and 0.96%, respectively. [16] No pharmacokinetic profiles of DM in UMs have been reported. Therefore the frequency of UMs was assigned to EM groups, given the enzymatic activity of CYP2D6 in UM group is the most close to 
Results
Model development
Simulation of plasma drug concentration-time profiles
Predicted mean pharmacokinetic parameter values of DM for the ten virtual trials were compared with the corresponding observed mean values in EM, IM, and PM subjects, respectively, as shown in Table 3 . Predicted mean pharmacokinetic parameter values of DX for the ten virtual trials were compared with the corresponding observed mean values in EM and IM subjects, respectively, as shown in Table 4 . Simulated plasma concentration-time profiles of DM and DX following the single dosing of 30 mg DM were able to recover the observed data in EM, IM, and PM subjects, respectively, as shown in Figure 1 .
In EMs, the ratios of the simulated to the observed mean AUC and C max of DM in the entire virtual population were 1.01 and 0.81, within the predefined criterion of (Capon et al., 1996) . [7] b. Mean(SD) 
Plasma sampling time (h)
Observed Spearman's correlation coef.
Simulated Spearman's correlation coef. 
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Chinese were 1.84, 47.9, 49.3 and 0.96%, respectively, [16] it was unlikely to include subjects with UM or PM phenotype in a small trial in Chinese. Therefore the results from small trials could not be extrapolated to PM or UM groups.
In the present study, the PBPK models of DM and its metabolite DX in EM, IM, 
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Graphical abstract
In the present study, a dynamic PBPK model was developed for DM and its active metabolite DX in three CYP2D6 phenotype groups (EM, IM, and PM). 
